Literature DB >> 3781329

Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile.

R P Bolton, M A Culshaw.   

Abstract

Faecal metronidazole and hydroxymetronidazole concentrations measured by high pressure liquid chromatography are reported during 10 episodes of Clostridium difficile colitis in nine patients. Bactericidal faecal concentrations were present in all patients with acute disease receiving oral or intravenous metronidazole, and all responded to therapy. Metronidazole and hydroxymetronidazole concentrations fell as the diarrhoea improved and neither substance was detectable in the faeces of five patients after recovery. This demonstration of intracolonic therapeutic concentrations of metronidazole supports the clinical experience of oral metronidazole being effective in the treatment of antibiotic associated diarrhoea caused by C difficile and also suggests a potential role for intravenous metronidazole in this disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3781329      PMCID: PMC1433873          DOI: 10.1136/gut.27.10.1169

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  20 in total

1.  Oral metronidazole in Clostridium difficile colitis.

Authors:  N L Pashby; R P Bolton; R J Sherriff
Journal:  Br Med J       Date:  1979-06-16

2.  Oral vancomycin for antibiotic-associated pseudomembranous colitis.

Authors:  F Tedesco; R Markham; M Gurwith; D Christie; J G Bartlett
Journal:  Lancet       Date:  1978-07-29       Impact factor: 79.321

3.  Clinical and laboratory observations in Clostridium difficile colitis.

Authors:  J G Bartlett; N S Taylor; T Chang; J Dzink
Journal:  Am J Clin Nutr       Date:  1980-11       Impact factor: 7.045

4.  Treatment of pseudomembranous colitis with oral metronidazole after relapse following vancomycin.

Authors:  D Oldenburger; J A Miller
Journal:  Am J Gastroenterol       Date:  1980-10       Impact factor: 10.864

5.  Treatment and prevention of antimicrobial agent-induced colitis and diarrhae.

Authors:  W L George; R D Rolfe; S M Finegold
Journal:  Gastroenterology       Date:  1980-08       Impact factor: 22.682

6.  Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters.

Authors:  R Fekety; J Silva; R Toshniwal; M Allo; J Armstrong; R Browne; J Ebright; G Rifkin
Journal:  Rev Infect Dis       Date:  1979 Mar-Apr

7.  Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea.

Authors:  M R Keighley; D W Burdon; Y Arabi; J A Williams; H Thompson; D Youngs; M Johnson; S Bentley; R H George; G A Mogg
Journal:  Br Med J       Date:  1978-12-16

8.  Treatment of antibiotic-associated colitis with vancomycin.

Authors:  R Fekety; J Silva; B Buggy; H G Deery
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

9.  Excretion of metroindazole in human bile. Investigations of hepatic bile, common duct bile, and gallbladder bile.

Authors:  M L Nielsen; T Justesen
Journal:  Scand J Gastroenterol       Date:  1977       Impact factor: 2.423

10.  [Metronidazole circulation and fate in the digestive tract of the rat after oral administration. Absorption of metronidazole by the digestive mucosa].

Authors:  P Populaire; F Benazet; S Pascal; G Lebreton; B Decouvelaere; L Guillaume
Journal:  Therapie       Date:  1971 May-Jun       Impact factor: 2.070

View more
  73 in total

1.  Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection.

Authors:  Judith M Wenisch; Daniela Schmid; Hung-Wei Kuo; Franz Allerberger; Verena Michl; Philip Tesik; Gerhard Tucek; Hermann Laferl; Christoph Wenisch
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

Review 2.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

Review 3.  Drug-induced Clostridium difficile-associated disease.

Authors:  M L Job; N F Jacobs
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

4.  Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid.

Authors:  T Norén; M Wullt; Thomas Akerlund; E Bäck; I Odenholt; L G Burman
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

5.  Can metronidazole still be used for treatment of Clostridium difficile infections?

Authors:  Haihui Huang; Carl Erik Nord
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

6.  Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.

Authors:  Wafa N Al-Nassir; Ajay K Sethi; Yuejin Li; Michael J Pultz; Michelle M Riggs; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

Review 7.  Recurrent Clostridium difficile infection: what are the treatment options?

Authors:  Claire M F van Nispen tot Pannerden; Annelies Verbon; Ernst J Kuipers
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

8.  Management of Clostridium difficile Infection.

Authors:  Layth S Al-Jashaami; Herbert L DuPont
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-10

Review 9.  Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Authors:  Kathleen Mullane
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

10.  Clostridium difficile infection in children: epidemiology and risk of recurrence in a low-prevalence country.

Authors:  A Lo Vecchio; L Lancella; C Tagliabue; C De Giacomo; S Garazzino; M Mainetti; L Cursi; E Borali; M V De Vita; E Boccuzzi; L Castellazzi; S Esposito; A Guarino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-30       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.